<DOC>
	<DOCNO>NCT00043875</DOCNO>
	<brief_summary>This study conduct evaluate effectiveness safety LAMICTAL add current therapy pediatric patient age 1-24 month old partial seizure . The medication use study approve FDA adjunctive treatment partial seizures patient 2 year old .</brief_summary>
	<brief_title>Pediatric Epilepsy Trial Subjects 1-24 Months</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>INCLUSION CRITERIA : Have confident diagnosis epilepsy Must experience 4 reliably detectable partial seizure per month receive least 1 antiepileptic drug ( AED ) Must weigh least 7 lb currently receive enzyme induce antiepileptic drug ( EIADs ) OR weigh least 15 lb currently receive nonenzyme induce antiepileptic drug ( nonEIADs ) Have underlie chronic metabolism problem Have normal lab result Have normal electrocardiogram ( ECG ) EXCLUSION CRITERIA : Have diagnosis severe , progressive myoclonus . Have seizure relate epilepsy . Have previously demonstrate sensitivity allergic reaction study drug relate compound . Have progressive unstable condition nervous system . Used experimental medication within 30 enrollment study . Have significant , chronic heart , kidney , liver stomach/intestinal ( GI ) condition . Current use medication felbamate . Current use adrenocorticotrophic hormone ( ACTH ) . Following ketogenic diet . Receiving vagal nerve stimulation ( VNS ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>partial seizure</keyword>
	<keyword>pediatric</keyword>
	<keyword>epilepsy</keyword>
</DOC>